Innovent Biologics (Suzhou)
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (174)
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Started: 4/1/2026
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
Started: 4/23/2026
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Started: 12/29/2025
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Started: 9/10/2025
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Started: 8/4/2025
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Started: 6/12/2025
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Started: 3/17/2025
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)
Started: 6/30/2024
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
Started: 5/9/2025
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Started: 8/23/2018
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease
Started: 10/20/2023
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Started: 2/7/2021
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
Started: 2/29/2024
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Started: 10/10/2023
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Started: 3/15/2024
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
Started: 9/21/2023
A Study of IBI362 in Participants With Obesity or Overweight
Started: 11/14/2022
A Study of IBI306 in Participants With Hypercholesterolemia
Started: 2/9/2021
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
Started: 2/10/2023
A Study of IBI362 9 mg in Chinese Adults With Obesity
Started: 12/27/2023
A Study of IBI362 in Participants With Type 2 Diabetes
Started: 1/6/2023
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Started: 1/6/2023
A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
Started: 5/25/2023
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Started: 7/11/2019
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Started: 12/24/2018
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Started: 4/17/2020
A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)
Started: 3/10/2021
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Started: 12/19/2018
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Started: 9/1/2017
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Started: 9/28/2018
Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
Started: 4/29/2020
Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
Started: 11/28/2016
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
Started: 8/22/2016
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Started: 9/22/2016
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Started: 6/5/2026
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Started: 4/17/2026
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Started: 4/20/2026
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
Started: 12/31/2025
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Started: 2/6/2026
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Started: 7/1/2025
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Started: 8/26/2025
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Started: 4/1/2025
A Study of IBI363 in Subjects With Advanced Melanoma
Started: 10/19/2023
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Started: 2/24/2025
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Started: 4/8/2024
IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer
Started: 2/4/2026
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
Started: 2/6/2026
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
Started: 7/1/2022
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
Started: 6/8/2021
A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease
Started: 9/4/2024
A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors
Started: 8/31/2025
A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics
Started: 8/28/2023
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Started: 7/10/2024
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
Started: 8/27/2020
The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Started: 7/31/2023
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
Started: 6/29/2022
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Started: 4/7/2020
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
Started: 3/3/2020
A Study of IBI311 in Subjects With Active Thyroid Eye Disease
Started: 2/14/2023
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
Started: 9/23/2021
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Started: 9/6/2021
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Started: 12/8/2020
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
Started: 3/7/2019
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
Started: 9/29/2019
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Started: 3/25/2022
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Started: 5/10/2017
Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Started: 8/23/2017
Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Started: 3/30/2017
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Started: 10/26/2022
Safety and Preliminary Activity of BI115 in Advanced SCLC
Started: 5/21/2026
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Started: 4/18/2026
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Started: 4/18/2025
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Started: 4/4/2023
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
Started: 12/30/2024
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 1/10/2025
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Started: 9/20/2022
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 1/8/2025
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Started: 7/29/2024
A Study of IBI363 in Subjects With Advanced Malignancies
Started: 6/15/2024
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 11/14/2023
Study of IBI3016 in People With Mild or Moderate Hypertension Patients
Started: 5/15/2026
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis
Started: 4/30/2026
A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
Started: 4/24/2026
A Mutiple-dose Study of IBI3033 in Healthy Participants
Started: 3/18/2026
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
Started: 8/22/2022
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
Started: 8/9/2023
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
Started: 12/31/2025
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 8/19/2024
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
Started: 12/8/2025
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Started: 6/17/2025
A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 3/12/2024
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
Started: 2/26/2024
A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations
Started: 9/13/2021
A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours
Started: 1/16/2024
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
Started: 7/14/2024
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Started: 8/30/2024
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
Started: 1/5/2024
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
Started: 5/14/2025
Safety and Tolerability of IBI355 in Healthy Volunteers
Started: 5/20/2024
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
Started: 4/15/2019
A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers
Started: 5/31/2021
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy
Started: 5/7/2021
Safety and Tolerance Study of IBI355 in Health Volunteers
Started: 10/30/2023
A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors
Started: 10/27/2021
Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma
Started: 6/16/2020
A Dose Escalation Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration
Started: 2/27/2023
A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)
Started: 3/5/2024
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
Started: 5/5/2023
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Started: 12/2/2021
A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19
Started: 1/6/2022
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Started: 6/16/2020
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Started: 4/6/2023
A Dose Escalation Study of IBI324 in Subjects With Diabetic Macular Edema
Started: 8/1/2022
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
Started: 11/26/2019
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Started: 9/25/2020
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Started: 7/28/2023
A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Started: 1/14/2021
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors
Started: 7/31/2020
Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers
Started: 3/6/2023
A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor
Started: 12/28/2021
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.
Started: 7/21/2021
IBI397 or Combination Therapies in Patients With Advanced Malignancies
Started: 4/14/2022
Phase I Study of Sintilimab in Healthy Chinese Male Subjects
Started: 4/13/2022
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Started: 2/8/2022
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Started: 9/7/2021
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Started: 1/25/2021
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
Started: 6/6/2021
Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345
Started: 12/13/2021
A Study of IBI353 (Orismilast) in Chinese Healthy Adults
Started: 11/30/2022
Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Started: 12/1/2020
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
Started: 12/24/2020
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial
Started: 11/24/2020
A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19
Started: 12/31/2021
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
Started: 5/22/2020
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
Started: 6/21/2021
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
Started: 6/24/2021
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Started: 9/25/2018
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Started: 4/2/2020
A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies
Started: 12/14/2020
Study of IBI318 in Participants With Advanced Malignancies
Started: 4/19/2019
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
Started: 7/23/2021
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Started: 11/12/2021
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Started: 2/13/2019
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
Started: 9/30/2020
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Started: 11/1/2022
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Started: 10/19/2016
Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects
Started: 8/27/2020
Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects
Started: 7/30/2021
A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced Malignancies
Started: 1/10/2019
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Started: 2/19/2019
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
Started: 5/28/2020
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
Started: 9/12/2020
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
Started: 3/26/2020
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Started: 6/29/2020
Clinical Study of IBI362 in Healthy Chinese Male Subjects
Started: 3/3/2021
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Started: 6/27/2018
A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS
Started: 8/24/2020
Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.
Started: 11/27/2017
Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
Started: 3/9/2017
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Started: 6/18/2020
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Started: 12/13/2016
Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers
Started: 10/27/2016
Clinical Trials of IBI3035 in Healthy Subjects
Started: 5/8/2026
Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Started: 6/1/2026
A Study of IBI3031 in Participants With Thyroid Eye Disease
Started: 5/30/2026
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
Started: 12/30/2025